Get notified when OTLK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern, and the auditor's report includes an explanatory paragraph to that effect.
- Class Action Lawsuit (unchanged) — The company and its officers face a class action and shareholder derivative lawsuit, which could result in substantial costs and divert management attention.
Outlook Therapeutics prices $55M unit offering at $0.99/share with warrants; net proceeds fund LYTENAVA launch
Filed August 14, 2026 · ~1 min read
Key Changes
-
high
Outlook Therapeutics is offering 55,555,556 shares with warrants at $0.99 per unit, raising $55M gross before underwriting discounts.
The Offering verify on EDGAR → -
high
Net proceeds to the company are approximately $51.1M (or $58.8M if underwriters' option fully exercised), after discounts and expenses.
Use of Proceeds verify on EDGAR → -
high
Proceeds will fund the commercial launch of LYTENAVA in the US and working capital, with runway into Q2 2027.
Use of Proceeds verify on EDGAR →
5 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade OTLK commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify